Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
07/10/2026 13:44
BRIEF-Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million Oct 7 (Reuters) - Ultragenyx Pharmaceutical Inc. RARE.O:
ULTRAGENYX ENTERS INTO AGREEMENT TO SELL RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER FOR $210 MILLION
ULTRAGENYX PHARMACEUTICAL - ENTERS AGREEMENT TO SELL PRIORITY REVIEW VOUCHER FOR $210 MILLION
Source text: ID:nGNX8cHpXF
Further company coverage: RARE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ultragenyx Pharmaceutical
See all newsBrief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx